Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) rose 2.3% during mid-day trading on Friday . The stock traded as high as $148.94 and last traded at $148.66, with a volume of 92,971 shares trading hands. The stock had previously closed at $145.25.

ICPT has been the subject of several research reports. Leerink Swann reissued a “market perform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, March 23rd. Cowen and Company reissued a “buy” rating and issued a $212.00 price target on shares of Intercept Pharmaceuticals in a research report on Monday, March 28th. Credit Suisse Group AG initiated coverage on shares of Intercept Pharmaceuticals in a research report on Wednesday, March 30th. They issued an “outperform” rating and a $200.00 price target for the company. Goldman Sachs Group Inc. assumed coverage on shares of Intercept Pharmaceuticals in a research report on Wednesday, March 30th. They issued a “neutral” rating and a $114.00 price target for the company. Finally, JMP Securities restated a “buy” rating and set a $200.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, March 30th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $203.08.

The firm’s 50-day moving average price is $148.93 and its 200-day moving average price is $133.91. The company’s market capitalization is $3.66 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($5.17) EPS for the quarter, missing analysts’ consensus estimates of ($3.60) by $1.57. During the same period in the previous year, the firm earned ($1.78) earnings per share. On average, equities research analysts expect that Intercept Pharmaceuticals Inc. will post ($16.82) earnings per share for the current fiscal year.

In related news, CEO Mark Pruzanski sold 714 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $145.11, for a total transaction of $103,608.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Lisa Bright sold 251 shares of the stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total value of $34,512.50. Following the sale, the insider now directly owns 18,855 shares in the company, valued at $2,592,562.50. The disclosure for this sale can be found here.

Other large investors have added to or reduced their stakes in the company. California State Teachers Retirement System boosted its stake in Intercept Pharmaceuticals by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,529 shares of the biopharmaceutical company’s stock valued at $4,410,000 after buying an additional 400 shares during the period. Rhumbline Advisers boosted its stake in Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock valued at $2,367,000 after buying an additional 109 shares during the period. ProShare Advisors LLC boosted its stake in Intercept Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 20,213 shares of the biopharmaceutical company’s stock valued at $3,019,000 after buying an additional 1,130 shares during the period. New York State Common Retirement Fund boosted its stake in Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock valued at $5,586,000 after buying an additional 800 shares during the period. Finally, South Dakota Investment Council boosted its stake in Intercept Pharmaceuticals by 6.8% in the fourth quarter. South Dakota Investment Council now owns 36,200 shares of the biopharmaceutical company’s stock valued at $5,406,000 after buying an additional 2,300 shares during the period.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.